$9.51
+0.40 (+4.39%)
Open$9.41
Previous Close$9.11
Day High$10.63
Day Low$9.03
52W High$41.65
52W Low$21.31
Volume—
Avg Volume306.8K
Market Cap29.67M
P/E Ratio21.74
EPS$1.28
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+282.0% upside
Current
$9.51
$9.51
Target
$36.33
$36.33
$21.56
$36.33 avg
$42.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.14M | 4.29M | 4.24M |
| Net Income | -270,468 | -254,054 | -270,426 |
| Profit Margin | -6.5% | -5.9% | -6.4% |
| EBITDA | -483,031 | -431,767 | -494,923 |
| Free Cash Flow | -204,723 | -222,413 | -294,472 |
| Rev Growth | -4.9% | +3.8% | -2.6% |
| Debt/Equity | 0.13 | 0.14 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |